June 2016


ACT-AD Webinar on Clinical Meaningfulness/July 19/10 a.m. ET

Mark your calendars for Thursday, July 19, at 10 a.m. to 11 a.m. ET for an expert ACT-AD webinar on clinical meaningfulness. Experts for the webinar include: Russell “Rusty” Katz, M.D., Christina Sampaio, M.D., Ph.D., and Yaakov Stern, Ph.D. For additional information, please email Cynthia Bens.

ACT-AD’s Bens Speaks at Precision Medicine Briefing

ACT-AD Executive Director Cynthia Bens spoke at a Congressional Life Science Caucus Briefing about precision medicine on Capitol Hill. The briefing, which was hosted by Biocom and sponsored by Illumina, focused on the potential role precision medicine can play in the treatment of cancer, cystic fibrosis and Alzheimer’s disease. Bens discussed ACT-AD’s efforts to raise awareness about challenges and opportunities for advancing precision medicine in the treatment of Alzheimer’s disease, including an expert webinar on the subject and a meeting with the FDA and industry experts. To see Bens’ presentation at the event, please go here.

New Study Results Offer Hope for Reversing Memory Loss Caused by Alzheimer’s Disease

The results of a small trial have given experts hope that memory loss linked to Alzheimer’s disease could be reversed. According to researchers, 10 patients who had early Alzheimer’s (or its precursors) showed “unprecedented improvements” after undergoing a 36-point therapeutic program. This is the first time that reversal of memory loss has been objectively demonstrated. Learn more here.

Capitol Hill Briefing on Research at the NIA

The Friends of the National Institute on Aging will host a briefing about the groundbreaking aging research that is being supported by the National Institute on Aging (NIA) on Thursday, June 30, 2016, 2:00-3:00 p.m. at the Capitol Visitors Center, SVC 201, U.S. Capitol Building, Washington, D.C. To RSVP for the event, please go here.

Researchers Gain Insights into Amyloid Beta Proteins

Experts say that they have made a discovery that offers them clues into amyloid beta proteins. By making a subtle alteration to this protein, researchers created “a version of amyloid beta with a reduced rate of fibril formation, different fibril structure, and increased toxicity in cell culture compared to the normal or ‘wild type’ protein. To learn more about the study, go here.

Save the Date for ACT-AD’s Ninth Annual FDA/AD Allies Meeting/November 16

Mark your calendars! ACT-AD’s Ninth Annual FDA/AD Allies Meeting is set for Wednesday, November 16, 2016, at the Bethesda North Marriott Hotel and Conference Center (5701 Marinelli Road, North Bethesda, Maryland, 20852) Get more information here.